Company / Cash & Equivalents
DarioHealth Corp. Cash & Equivalents History
FY2014-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.7M
FY2018
5-year range
$1.1M / $3.7M
FY2014-FY2018
Trend
+240.2%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +240% YoY in FY2018, a notable deviation from the 4-year average annual change of +57%.
Based on SEC 10-K filings.
$4M in FY2018 with a 3-year CAGR of +36.8%.
Improved from $3M to $4M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +36.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +36.8%, indicating consistent growth.
- In FY2018, cash & equivalents increased 240.2% year-over-year.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -2.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2018 | $3.7M | +240.2% |
| FY2017 | $1.1M | -59.1% |
| FY2016 | $2.7M | +83.8% |
| FY2015 | $1.5M | -35.8% |
| FY2014 | $2.3M | - |
As of FY2018 · SEC 10-K Annual Filings · Updated Jun 24, 2026